Agree. Surely the time to give up on the GvHD-only strategy (in favour of CLBP) is looming if the FDA require a trial in adults that will take more than 12 months. This is especially so where the CLBP trial end points of pain relief and giving up opioids would be so obvious that it could end the trial early because of overwhelming efficacy, not to mention the financial cost benefit involved. The MSB Board has to be responsible for the overall strategy/direction of the company and they must have a Plan B, C, D etc.
rexlemestrocel-L in the treatment of chronic low back pain (CLBP), page-5
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |